MRX, Medicis Pharmaceutical Corp.
MRX engages in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States, Canada, and Europe.
MRX is dedicated to helping patients attain a healthy and youthful appearance and self-image. MRX's products address various conditions or aesthetic improvements, including facial wrinkles, glabellar lines, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, seborrheic dermatitis, and cosmesis.
MRX's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.
Recently, MRX reported its Fourth Quarter and Year-End 2010 Results
MRX reported revenues of approximately $700.0 million for the twelve months ended December 31, 2010, compared to revenues of approximately $571.9 million for the twelve months ended December 31, 2009, which represents an increase of approximately $128.1 million, or approximately 22.4%.
Additional Fiscal year 2010 Financial Highlights include
- GAAP EPS increased approximately 56.7%
- Gross profit margin of approximately 90.0%
- Cash flow from operations of approximately $178.4 million
MRX's Fourth Quarter 2010 Highlights include
- Revenues of $182 million
- Non-GAAP EPS of $0.60
- GAAP EPS of $0.37
More about MRX at www.medicis.com
NHPR, National Health Partners, Inc., NHPR.OB
These days the uninsured pay back more for care-and acquire less-than those with insurance.
But when the uninsured can not pay, health care providers adjust those costs to people who can pay-those who have insurance coverage. Which leads to higher prices for those who buy his or her insurance on the personal market, as well as personnel who get insurance policies for themselves and their families through their job.
The need for affordable healthcare alternatives has never been greater.
NHPR is a leading national healthcare savings organization that provides unique discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called "CARExpress."
NHPR's CARExpress is a network of hospitals, doctors, dentists, pharmacists and other healthcare providers comprised of over 1,000,000 medical professionals that have agreed to render their services and products to CARExpress members at discounted prices. CARExpress enables people to engage in point-of-service transactions directly with these providers and pay discounted prices that are similar in amount to those paid by insurance companies on behalf of their insureds.
CARExpress' programs offer savings on healthcare services to persons who are uninsured and underinsured and to those who purchase only high deductible or limited benefit medical insurance policies by providing access to the same PPOs that are utilized by employers that self-fund at least a portion of their employees' healthcare costs. CARExpress' programs are also used to supplement benefit plans and fill in the gaps created by the need to reduce health benefits to keep the costs of health insurance reasonable. CARExpress' programs are sold under the name CARExpress directly by the company and indirectly through resellers that privately label or co-brand its CARExpress membership programs and employers that offer CARExpress' programs to their employees.
More about NHPR at www.nationalhealthpartners.com
SNTA, Synta Pharmaceuticals Corp.
SNTA is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease.
SNTA has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All clinical candidates were invented internally by SNTA scientists using its compound library and discovery capabilities.
SNTA reported that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer (NSCLC) were presented at the International Association for the Study of Lung Cancer (IASLC) 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting. The trial is ongoing; final results are expected later this year.
Ganetespib (formerly STA-9090) is a potent, synthetic, small-molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a molecular chaperone required for the proper folding and activation of many cancer-promoting proteins, and is recognized as a key facilitator of cancer cell growth and survival. In preclinical experiments, ganetespib has shown activity in multiple tumor models both as a single agent and in combination with certain widely used cancer agents. Ganetespib is currently being evaluated in a broad range of cancer clinical trials including trials in non-small cell lung, breast, prostrate, pancreatic, colorectal, gastric, small cell lung, ocular melanoma, liver, GIST and hematologic cancers.
According to SNTA, Ganetespib has shown evidence of clinical and biological activity and has been well tolerated to date with no evidence of severe liver, ocular, cardiac or renal toxicity seen with other Hsp90 inhibitors. The most common adverse events seen to date have been diarrhea and fatigue, which have been manageable and reversible.
SNTA also reported that a Phase 2b/3 clinical trial of ganetespib (STA-9090) in combination with docetaxel in non-small cell lung cancer (NSCLC) will be initiated in the second quarter of 2011.
More about SNTA at www.syntapharma.com
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
Crown Equity Holdings Inc. (CRWE.OB) has received 3,000,000 shares of (144) restricted common stock from the company and anticipates receiving 3,000,000 shares of free trading shares from a third party for six months of advertisement services for National Health Partners Inc. (NHPR.OB).